[1] Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial. Retrieved September 23, 2024 from https://www.prnewswire.com/news-releases/immusoft-to-announce-positive-phase-1-data-for-first-engineered-b-cell-therapy-in-a-clinical-trial-302255551.html
[2] Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity. Retrieved September 23, 2024 from https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-regulatory-clearance-initiate-3
[3] Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors. Retrieved September 23, 2024 from https://pipelinereview.com/innate-pharma-announces-fda-clearance-of-the-ind-for-iph4502-a-nectin-4-adc-to-be-developed-in-solid-tumors/
[4] Metsera Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097. Retrieved September 24, 2024 from https://www.businesswire.com/news/home/20240924023447/en/Metsera-Reports-Highly-Competitive-Results-from-Ongoing-Trial-of-Novel-Potential-Once-Monthly-Injectable-GLP-1-Receptor-Agonist-MET-097
[5] Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease. Retrieved September 24, 2024 from https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-bio-initiates-phase-1-clinical-trial-vtp-1000#:~:text=Investigational%20immunotherapy%20candidate,%20VTP-1000,%20seeks%20to
[6] Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer. Retrieved September 27, 2024 from https://www.globenewswire.com/news-release/2024/09/26/2953686/0/en/Pasithea-Therapeutics-Announces-Positive-Initial-Safety-Tolerability-Pharmacokinetic-PK-and-Preliminary-Efficacy-Data-from-its-Phase-1-Clinical-Trial-of-PAS-004-in-Advanced-Cancer.html
[7] Enalare Receives FDA Clearance to Initiate the First Phase 1 Clinical Study of ENA-001 to Be Conducted in the United States. Retrieved September 27, 2024 from https://www.newswire.com/news/enalare-receives-fda-clearance-to-initiate-the-first-phase-1-clinical-22429358
[8] KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy. Retrieved September 27, 2024, from https://www.globenewswire.com/news-release/2024/09/24/2952011/0/en/KSQ-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-KSQ-004EX-a-CRISPR-Cas9-Engineered-Tumor-Infiltrating-Lymphocyte-eTIL-Therapy.html#:~:text=KSQ-004EX,%20an%20eTIL%20%C2%AE%20cell%20therapy
[9] Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome. Retrieved September 27, 2024, from https://www.globenewswire.com/news-release/2024/09/26/2954055/0/en/Minovia-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-Ib-Clinical-Trial-of-MNV-201-in-Low-Risk-Myelodysplastic-Syndrome.html
[10] Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366. Retrieved September 27, 2024, from https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-positive-interim-phase-1a-results
[11] Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024. Retrieved September 27, 2024, from https://www.prnewswire.com/news-releases/alkermes-to-present-positive-clinical-data-from-phase-1b-study-of-alks-2680-in-patients-with-narcolepsy-type-2-and-idiopathic-hypersomnia-at-sleep-europe-2024-302254991.html
[12] Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor). Retrieved September 27, 2024, from https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase
[13] Georgiamune Announces First Participant Dosed in First-In-Class Phase 1 Healthy Volunteers Trial of GIM-407. Retrieved September 27, 2024, from https://www.globenewswire.com/news-release/2024/09/24/2952226/0/en/Georgiamune-Announces-First-Participant-Dosed-in-First-In-Class-Phase-1-Healthy-Volunteers-Trial-of-GIM-407.html#:~:text=The%20company%20has%20initiated%20three%20first-in-class
[14] Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients. Retrieved September 27, 2024, from https://www.prnewswire.com/news-releases/poseida-therapeutics-reports-positive-interim-phase-1-results-for-allogeneic-car-t-therapy-p-bcma-allo1-with-high-overall-response-rates-in-heavily-pretreated-relapsedrefractory-multiple-myeloma-patients-302261471.html